AFID Therapeutics ^Company

Afid Therapeutics, Inc. develops chemical and biochemical technologies and strategies that are used in the design, discovery, delivery, and development of new drugs. Its products include lactones and esters acids, hydroxy cyclopentane carboxylic acids and derivatives, hydroxy cyclopentane acetic acids and derivatives, amino acids, cyclopentane amino alcohols, cyclopentanones, bicyclic amines and advanced diamines, amino alcohols and diols, unprotected amino diols, diamines, and oxathiolanes and oxazolidinones. The company also involves in the development of a platform of chiral chemical entities to emulate structural, reactive, and physicochemical aspects of biomolecules that potentiate and direct the chemistry of life processes. In addition, it offers ring systems in various screening collections, which include piperazines, oxazolines, oxazolidinones, morpholines, pyrrolidines, pyrrolidones, aza-sugars, macrolides, lactones, lactams, thiolactams, cyclopentanes, furans, pyrans, quinolines, isoquinolines, quinolones, purines, pyridines, pyrimidines, imidazoles, benzimidazoles, triazoles plus many more. Other functionalities include sulfonamides, phosphates, phosphonates, sulfates, sulfonates, alcohols, acids, amines, and oximes, as well as carbohydrate derivatives, nucleoside analogs, and oligosaccharides. The company’s technology base utilizes the structural richness of carbohydrates to allow intervention and therapies across a range of disease spectrum, including bacterial and viral infections, cancer, autoimmune disorders, cardiovascular disorders, diabetes, and Alzheimer's and other neurological disorders. Its drug targets include kinases, phosphatases, nucleases, glycosidases, glycosyltransferases, ribosomes, cell membranes, and nucleic acids. The company was founded in 2003 and is based in Lansing, Michigan.